+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Pipeline Review, H2 2018

  • ID: 4658211
  • Drug Pipelines
  • October 2018
  • Region: Global
  • 80 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • BeyondSpring Inc
  • Novartis AG
  • Sanofi
  • Shire Plc
  • MORE
Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Pipeline Review, H2 2018

Summary

According to the recently published report 'Caspase 3 - Pipeline Review, H2 2018'; Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) pipeline Target constitutes close to 13 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes.

Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Caspase-3 is a caspase protein encoded by the CASP3 gene. It interacts with caspase-8 and caspase-9. It cleaves and activates sterol regulatory element binding proteins (SREBPs) between the basic helix-loop-helix leucine zipper domain and the membrane attachment domain. It cleaves and activates caspase-6, -7 and -9. It is involved in the cleavage of huntingtin. It triggers cell adhesion in sympathetic neurons through RET cleavage.

The report 'Caspase 3 - Pipeline Review, H2 2018' outlays comprehensive information on the Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 6 and 1 respectively.

Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Gastrointestinal, Genito Urinary System And Sex Hormones, Cardiovascular, Infectious Disease, Central Nervous System, Hematological Disorders, Immunology, Metabolic Disorders, Ophthalmology, Respiratory and Toxicology which include indications Colorectal Cancer, Glomerulonephritis, Hepatocellular Carcinoma, Inflammatory Bowel Disease, Age Related Macular Degeneration, Alzheimer's Disease, Autoimmune Hepatitis, Bladder Cancer, Chemotherapy Induced Neutropenia, Diabetic Retinopathy, Febrile Neutropenia, Glioblastoma Multiforme (GBM), Hepatitis C, Liver Cirrhosis, Liver Failure (Hepatic Insufficiency), Liver Fibrosis, Liver Transplant Rejection, Metastatic Brain Tumor, Metastatic Breast Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Multiple Myeloma (Kahler Disease), Multiple Sclerosis, Myocardial Infarction, Non Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepatitis (NASH), Non-Small Cell Lung Cancer, Parkinson's Disease, Portal Hypertension, Primary Sclerosing Cholangitis, Prostate Cancer, Pulmonary Fibrosis, Renal Failure, Small-Cell Lung Cancer, Solid Tumor, Spinal Cord Injury, Stroke, Traumatic Brain Injury and Zika Virus Infections.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56)
  • The report reviews Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • BeyondSpring Inc
  • Novartis AG
  • Sanofi
  • Shire Plc
  • MORE
Introduction

Report Coverage

Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Overview

Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Companies Involved in Therapeutics Development

BeyondSpring Inc

Conatus Pharmaceuticals Inc

New World Laboratories Inc

Novartis AG

Sanofi

Shire Plc

Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Drug Profiles

1G3-Cu - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BaxB-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BaxG-03 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

emricasan - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

emricasan - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

flavokawain A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein to Activate Caspases for Age Related Macular Degeneration, Diabetic Retinopathy and Solid Tumors - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IDN-7314 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MBRI-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NWL-283 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

plinabulin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate Caspase-3 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate Procaspase-3 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Dormant Products

Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Discontinued Products

Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Product Development Milestones

Featured News & Press Releases

Oct 04, 2018: Study opens of BeyondSpring’s lead asset, Plinabulin, and Nivolumab + Ipilimumab in Small-Cell Lung Cancer

Oct 03, 2018: Beyondspring to present clinical trial data at three upcoming scientific conferences

Sep 25, 2018: BeyondSprings lead asset, Plinabulin, continues to demonstrate clinical superiority versus standard of care for Neutropenia

Sep 20, 2018: Conatus Pharmaceuticals to Host Analyst and Investor Symposium on Portal Hypertension

Sep 19, 2018: BeyondSpring strengthens intellectual property portfolio with newly granted U.S. Patent for Plinabulin

Sep 06, 2018: BeyondSpring’s lead asset, Plinabulin, shows superior efficacy compared to Neulasta for prevention of thrombocytopenia induced by Docetaxel in phase 2 trial

Aug 15, 2018: BeyondSpring to Present Clinical Trial Data on Lead Asset, Plinabulin, at IASLC World Conference on Lung Cancer

Jul 02, 2018: Conatus Pharmaceuticals’ Pan-caspase Inhibitor Emricasan Improves Survival and Portal Hypertension in a Mouse Model of Cirrhosis

Jun 25, 2018: BeyondSpring’s Principal Investigator in China for Chemotherapy-Induced Neutropenia Delivered Keynote Presentation at 12th Annual Chinese Symposium on Medical Oncology and 7th Annual Meeting of the Chinese Association for Clinical Oncologists

May 17, 2018: BeyondSpring to Present Positive Data From Prospective Phase 2 Trial Comparing Plinabulin to Neulasta for the Prevention of Chemotherapy-Induced Neutropenia at 2018 ASCO Annual Meeting

Apr 30, 2018: Conatus Announces Completion of Enrollment in ENCORE-PH Phase 2b Clinical Trial of Emricasan in Patients with NASH Cirrhosis and Severe Portal Hypertension

Apr 25, 2018: BeyondSpring to Present Neutropenia Clinical Trial Data on Lead Asset, Plinabulin, at 2018 ASCO Annual Meeting

Apr 18, 2018: Conatus Pharmaceuticals IDN-7314 Pan-caspase Inhibitor Reduces Hepatic Tissue Factor-Driven Coagulation In Vitro and In Vivo

Apr 17, 2018: BeyondSpring Presents Lead Asset’s Mechanism Data for Prevention of Chemotherapy-Induced Neutropenia

Apr 09, 2018: Conatus Pharmaceuticals Announces Upcoming Oral Presentation at EASL Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indications, H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Number of Products under Investigation by Universities/Institutes, H2 2018

Products under Investigation by Universities/Institutes, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by BeyondSpring Inc, H2 2018

Pipeline by Conatus Pharmaceuticals Inc, H2 2018

Pipeline by New World Laboratories Inc, H2 2018

Pipeline by Novartis AG, H2 2018

Pipeline by Sanofi, H2 2018

Pipeline by Shire Plc, H2 2018

Dormant Products, H2 2018

Dormant Products, H2 2018 (Contd..1), H2 2018

Dormant Products, H2 2018 (Contd..2), H2 2018

Dormant Products, H2 2018 (Contd..3), H2 2018

Discontinued Products, H2 2018

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • BeyondSpring Inc
  • Conatus Pharmaceuticals Inc
  • New World Laboratories Inc
  • Novartis AG
  • Sanofi
  • Shire Plc
Note: Product cover images may vary from those shown
Adroll
adroll